BioK

The main research interest of BioK´s group is to develop updated therapies targeting relevant multi-drug resistant infections caused by the most challenging pathogens highlighted by the WHO. BioK´s group seeks to develop novel chemical entities with a new mechanism of action by disabling the viability of the bacteria (antibiotic) and/or its capacity to cause infection (pathogenicity) by targeting unexplored bacterial objectives. For the design of the compounds, the group employs X-ray crystallography of enzyme/inhibitor complexes, and computational enzymology and modelling biological catalysts (molecular dynamic simulations, quantum mechanics/molecular mechanics). These tools allow them to address more complex issues from a multidisciplinary perspective beyond chemistry.